{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:41:57Z","timestamp":1768642917419,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.vaccine.2020.03.027","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T09:02:51Z","timestamp":1584435771000},"page":"3295-3299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats"],"prefix":"10.1016","volume":"38","author":[{"given":"Kosuke","family":"Murakami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Someya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.03.027_b0005","unstructured":"World Health Organization. WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use (GAPIII); 2015. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208872\/WHO_POLIO_15.05_eng.pdf"},{"key":"10.1016\/j.vaccine.2020.03.027_b0010","unstructured":"Global Polio Eradication Initiative. Global eradication of wild poliovirus type 2 declared. Declaration further milestone for globally-coordinated vaccine switch in 2016; 2015. http:\/\/polioeradication.org\/news-post\/global-eradication-of-wild-poliovirus-type-2-declared\/"},{"key":"10.1016\/j.vaccine.2020.03.027_b0015","unstructured":"World Health Organization. GAPIII Containment Certification Scheme; 2017. http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/10\/CCS.pdf"},{"key":"10.1016\/j.vaccine.2020.03.027_b0020","unstructured":"World Health Organization. Guidelines for the safe production and quality control of poliomyelitis vaccines. Replacement of Annex 2 of WHO Technical Report Series, No. 926. In: WHO Expert Committee on Biological Standardization: Sixty-nine report. WHO Technical Report Series; 2019. No. 1016, Annex 4. https:\/\/www.who.int\/biologicals\/vaccines\/Annex_4_WHO_TRS_1016_web4.pdf"},{"key":"10.1016\/j.vaccine.2020.03.027_b0025","unstructured":"World Health Organization. Preparing for the withdrawal of all oral polio vaccines (OPVs): Replacing trivalent OPV (tOPV) with bivalent OPV (bOPV); 2015. https:\/\/www.who.int\/immunization\/diseases\/poliomyelitis\/endgame_objective2\/oral_polio_vaccine\/OPVswitch-briefing-note-Feb2015.pdf"},{"key":"10.1016\/j.vaccine.2020.03.027_b0030","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1016\/j.vaccine.2014.07.065","article-title":"The sIPV Evaluation Group of NIID-Virology II. A national reference for inactivated polio vaccine derived from Sabin strains in Japan","volume":"32","author":"Shirato","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.027_b0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/infdis\/jit155","article-title":"Phase II and III clinical studies of diphtheria\u2013tetanus\u2013acellular pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV)","volume":"208","author":"Okada","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.027_b0040","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.vaccine.2014.11.015","article-title":"Development and introduction of inactivated poliovirus vaccines derived from Sabin strain in Japan","volume":"34","author":"Shimizu","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.027_b0045","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.vaccine.2016.11.017","article-title":"Polio vaccines: WHO position paper, March 2016 \u2013 recommendations","volume":"35","author":"World Health Organization","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.027_b0050","unstructured":"World Health Organization. Report on the WHO collaborative study to establish the 1st International Standard for Sabin inactivated polio vaccine (sIPV); 2018. https:\/\/www.who.int\/biologicals\/BS.2018.2338_sIPV_IS_Collaborative_Study_Report_version.pdf"},{"key":"10.1016\/j.vaccine.2020.03.027_b0055","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiz076","article-title":"sIPVSG. Differences in antigenic structure of inactivated poliovaccines made from Sabin live-attenuated and wild-type poliovirus strains: impact on vaccine potency assays","author":"Crawt","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.027_b0060","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: a progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2020.03.027_b0065","unstructured":"World Health Organization. Requirements for poliomyelitis vaccine (inactivated). In: WHO expert committee on biological standardization: Fifty-first report. WHO Technical Report Series; 2002. No. 910, Annex 2. https:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/polio\/WHO_TRS_910_Annex2_polioinactivated.pdf"},{"key":"10.1016\/j.vaccine.2020.03.027_b0070","unstructured":"World Health Organization. Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated). Replacement of Annex 2 of WHO Technical Report Series, No. 910. In: WHO Expert Committee on Biological Standardization: Sixty-fifth report. WHO Technical Report Series; 2014. No. 993, Annex 3. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/173739\/9789240694095_eng.pdf"},{"key":"10.1016\/j.vaccine.2020.03.027_b0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.biologicals.2018.02.001","article-title":"Evaluation of the use of various rat strains for immunogenic potency tests of Sabin-derived inactivated polio vaccines","volume":"52","author":"Someya","year":"2018","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2020.03.027_b0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0042-6822(57)90042-9","article-title":"The ratio of physical particles per infectious unit observed for poliomyelitis viruses","volume":"4","author":"Schwerdt","year":"1957","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.03.027_b0085","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1073\/pnas.80.16.5080","article-title":"Localization of a poliovirus type 1 neutralization epitope in viral capsid polypeptide VP1","volume":"80","author":"van der Werf","year":"1983","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:07Z","timestamp":1759401787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20303807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":17,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0264410X20303807"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}